Organization | Beijing Anzhen Hospital

Beijing Anzhen Hospital Report issue

Academic/Hospital Phase 1 Phase 4

Organization Overview

First Clinical Trial

2012

NCT01633359

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Anzhen hospital | Anzhen hospital Beijing China | Beijing Anzhen Hospital, No.2, Anzhen Road, Chaoyang District, Beijing, China | Ji Huang | Liang Zhang | Shao-Ping Nie

Active Ingredients

Drugs in Phase 4 Trials (5)

atorvastatin (lipitor) (2 trials)

cilostazol (pletal) (1 trial)

isoflurane (forane) (1 trial)

probucol (lorelco) (1 trial)

propofol (diprivan) (1 trial)

Drugs in Phase 1 Trials (1)

prusogliptin (1 trial)

Drugs in Other Trials (3)

Bismuth Subcitrate Potassium (Pylera) (1 trial)

rhodiola (1 trial)

xinkeshu (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Hypercholesterolemia (Phase 4)

Myocardial Ischemia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 9